AU2016228894B2 - Pancreatic endocrine progenitor cell therapies for the treatment of obesity and Type 2 diabetes (T2D) - Google Patents

Pancreatic endocrine progenitor cell therapies for the treatment of obesity and Type 2 diabetes (T2D) Download PDF

Info

Publication number
AU2016228894B2
AU2016228894B2 AU2016228894A AU2016228894A AU2016228894B2 AU 2016228894 B2 AU2016228894 B2 AU 2016228894B2 AU 2016228894 A AU2016228894 A AU 2016228894A AU 2016228894 A AU2016228894 A AU 2016228894A AU 2016228894 B2 AU2016228894 B2 AU 2016228894B2
Authority
AU
Australia
Prior art keywords
cells
subject
pancreatic endocrine
population
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016228894A
Other languages
English (en)
Other versions
AU2016228894A1 (en
Inventor
Jennifer E. BRUIN
Timothy J. Kieffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CCS Ventures Ltd
Original Assignee
CCS Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56879832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016228894(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CCS Ventures Ltd filed Critical CCS Ventures Ltd
Publication of AU2016228894A1 publication Critical patent/AU2016228894A1/en
Assigned to PETUNIA RESOURCES LTD. reassignment PETUNIA RESOURCES LTD. Request for Assignment Assignors: Bruin, Jennifer, KIEFFER, TIMOTHY
Assigned to CCS VENTURES LIMITED reassignment CCS VENTURES LIMITED Request for Assignment Assignors: PETUNIA RESOURCES LTD.
Application granted granted Critical
Publication of AU2016228894B2 publication Critical patent/AU2016228894B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016228894A 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and Type 2 diabetes (T2D) Active AU2016228894B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131540P 2015-03-11 2015-03-11
US62/131,540 2015-03-11
PCT/CA2016/000072 WO2016141460A1 (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Publications (2)

Publication Number Publication Date
AU2016228894A1 AU2016228894A1 (en) 2017-11-02
AU2016228894B2 true AU2016228894B2 (en) 2021-03-04

Family

ID=56879832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016228894A Active AU2016228894B2 (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and Type 2 diabetes (T2D)

Country Status (7)

Country Link
US (2) US10772917B2 (enExample)
EP (1) EP3268016B1 (enExample)
JP (1) JP6847044B2 (enExample)
CN (1) CN107530379A (enExample)
AU (1) AU2016228894B2 (enExample)
CA (1) CA2979293C (enExample)
WO (1) WO2016141460A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951136B2 (en) 2017-12-12 2024-04-09 The Regents Of The University Of California Preservation of pancreatic islet grafts in the extrahepatic space
US11530211B2 (en) 2018-01-18 2022-12-20 Daiichi Sankyo Company, Limited Dihydroindolizinone derivative
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CA3139294A1 (en) 2019-05-22 2020-11-26 The Cleveland Clinic Foundation Generating dorsal foregut, and anterior domain, endoderm cells
CN110585242A (zh) * 2019-10-15 2019-12-20 南通大学 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2022043518A1 (en) * 2020-08-28 2022-03-03 Novo Nordisk A/S Method for screening in vitro population of stem cell derived beta like cells and novel markers thereof
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120039955A1 (en) * 2010-08-12 2012-02-16 Janssen Biotech, Inc. Treatment of Diabetes with Pancreatic Endocrine Precursor Cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JP2005533480A (ja) * 2001-11-09 2005-11-10 アーテセル・サイエンシズ・インコーポレーテツド 脂肪組織由来間質細胞の膵内分泌分化およびその使用
JP2005527224A (ja) * 2002-05-24 2005-09-15 ワラタ ファーマシューティカルズ， インコーポレイテッド 糖尿病の処置
EP1539928A4 (en) * 2002-09-06 2006-09-06 Amcyte Inc CD56-POSITIVE HUMAN ADULTS PANCREATIC ENDOCRINE PRECURSOR CELLS
ES2569780T3 (es) 2003-06-27 2016-05-12 DePuy Synthes Products, Inc. Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
CN1589904A (zh) * 2003-09-01 2005-03-09 北京大学 造血干细胞动员剂制备治疗糖尿病药物的用途
JP2006149380A (ja) * 2004-10-27 2006-06-15 Kobe Univ 遺伝子改変動物の新規用途
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US20080233087A1 (en) * 2006-10-31 2008-09-25 Shamblott Michael J Methods for identifying, isolating, and utilizing endocrine progenitor cells from adult human pancreata
DE602007005402D1 (de) * 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
CN107574142B (zh) 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
WO2009137844A2 (en) * 2008-05-09 2009-11-12 Vistagen Therapeutics, Inc. Pancreatic endocrine progenitor cells derived from pluripotent stem cells
WO2010092163A2 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
PH12012500818A1 (en) 2009-10-29 2019-11-29 Janssen Biotech Inc Pluripotent stem cells
WO2011160066A1 (en) * 2010-06-17 2011-12-22 Regents Of The University Of Minnesota Production of insulin producing cells
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120039955A1 (en) * 2010-08-12 2012-02-16 Janssen Biotech, Inc. Treatment of Diabetes with Pancreatic Endocrine Precursor Cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. LIANG ET AL, "Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced...", DIABETES OBES METAB, 2012, vol. 14, no. 9 *
NOGUCHI, H. "Pancreatic Stem/Progenitor Cells for the Treatment of Diabetes", Rev Diabet Stud., 2010, vol. 7, no. 2. pages 105-111 *
REZANIA et al., "Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells''.", NATAURE BIOTECHNOLOGY, (2014-09-11), vol. 32, no. 11, ISSN 1087-0156, pages 1121 - 33 *
XIU-FENG HUA ET AL, "Pancreatic Insulin-Producing Cells Differentiated from Human Embryonic Stem Cells Correct Hyperglycemia in SCID/NOD Mice, an Animal Model of Diabetes", PLOS ONE, (2014-07-10), vol. 9, no. 7 *

Also Published As

Publication number Publication date
WO2016141460A1 (en) 2016-09-15
CN107530379A (zh) 2018-01-02
CA2979293A1 (en) 2016-09-15
JP6847044B2 (ja) 2021-03-24
US20210015872A1 (en) 2021-01-21
US20180055890A1 (en) 2018-03-01
EP3268016B1 (en) 2021-04-28
CA2979293C (en) 2022-01-04
JP2018507889A (ja) 2018-03-22
US10772917B2 (en) 2020-09-15
EP3268016A1 (en) 2018-01-17
EP3268016A4 (en) 2018-12-12
AU2016228894A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
US20210015872A1 (en) Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)
JP7354026B2 (ja) ＳＣ－β細胞及び組成物並びにその生成方法
RU2351648C2 (ru) Дифференцировка стромальных клеток, полученных из жировой ткани, в эндокринные клетки поджелудочной железы и их использование
Navarro-Tableros et al. Islet-like structures generated in vitro from adult human liver stem cells revert hyperglycemia in diabetic SCID mice
KR20200087201A (ko) 섬세포 제조 조성물 및 사용 방법
JP2017521089A (ja) 膵内分泌細胞の入手方法
KR20150067945A (ko) 인간 다능성 줄기세포로부터의 인슐린 생산 베타 세포의 내분비 응집체의 제조 방법
JP2019503697A (ja) 明細書
US11951136B2 (en) Preservation of pancreatic islet grafts in the extrahepatic space
WO2020035480A1 (en) Viable pancreatic islet-like cell structures and a method of preparing thereof
WO2014129628A1 (ja) 多能性幹細胞から膵ランゲルハンス島を製造する方法
US20130034525A1 (en) Beta iselets-like cells derived from whole bone marrow
Watanabe et al. An engineered innate repair receptor agonist, ARA 290, protects rat islets from cytokine-induced apoptosis
Samuelson Sca-1 positive pancreatic progenitor cells: a replacement for transplanted islets

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PETUNIA RESOURCES LTD.

Free format text: FORMER APPLICANT(S): KIEFFER, TIMOTHY; BRUIN, JENNIFER

PC1 Assignment before grant (sect. 113)

Owner name: CCS VENTURES LIMITED

Free format text: FORMER APPLICANT(S): PETUNIA RESOURCES LTD.

FGA Letters patent sealed or granted (standard patent)